Discovery is a complex and high-risk process in drug development, as researchers strive to identify and advance promising therapeutic candidates. It requires scientific prowess, advanced technologies, and strategic vision to navigate through potential obstacles with agility. With this episode, Big4Bio is kicking off an occasional series on discovery sciences with Charles River Labs, which, over the past five years, has contributed to more than 80 percent of novel FDA-approved drugs. We spoke with Charles River Labs' chief scientific officer of discovery Justin Bryans, and Charles River Labs' vice president and chief scientific officer for discovery and safety assessments, Steve Bulera, about the challenges of drug discovery, why every moment matters, and the benefits of the collaborative approach Charles River takes in working with its partners.
All content for The Big4Bio Podcast is the property of Big4Bio and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Discovery is a complex and high-risk process in drug development, as researchers strive to identify and advance promising therapeutic candidates. It requires scientific prowess, advanced technologies, and strategic vision to navigate through potential obstacles with agility. With this episode, Big4Bio is kicking off an occasional series on discovery sciences with Charles River Labs, which, over the past five years, has contributed to more than 80 percent of novel FDA-approved drugs. We spoke with Charles River Labs' chief scientific officer of discovery Justin Bryans, and Charles River Labs' vice president and chief scientific officer for discovery and safety assessments, Steve Bulera, about the challenges of drug discovery, why every moment matters, and the benefits of the collaborative approach Charles River takes in working with its partners.
Leveraging Synergies: How a Merger Provides Speed, Flexibility, and a Unified Offering for Customers
The Big4Bio Podcast
20 minutes 52 seconds
6 months ago
Leveraging Synergies: How a Merger Provides Speed, Flexibility, and a Unified Offering for Customers
In 2022, Charles River Laboratories acquired the vivarium operation services provider Explora BioLabs. The acquisition both complemented and expanded the operations of CRADL (Charles River Accelerator and Development Lab), which is part of Charles River’s Insourcing Solutions business. Now, three years later, the company has built a consistent brand, set of services, and unified offering across its North American locations based on the best of both companies. And, Explora BioLabs clients now have direct access to Charles River’s other products and services. We spoke to Charlie Cook, Senior Director of Operations for Charles River Labs, and Julie Freebersyser, Executive Director NA Insourcing Solutions for Charles River Labs, about the merger, the benefits it has brought, and the greater flexibility it provides its clients.
The Big4Bio Podcast
Discovery is a complex and high-risk process in drug development, as researchers strive to identify and advance promising therapeutic candidates. It requires scientific prowess, advanced technologies, and strategic vision to navigate through potential obstacles with agility. With this episode, Big4Bio is kicking off an occasional series on discovery sciences with Charles River Labs, which, over the past five years, has contributed to more than 80 percent of novel FDA-approved drugs. We spoke with Charles River Labs' chief scientific officer of discovery Justin Bryans, and Charles River Labs' vice president and chief scientific officer for discovery and safety assessments, Steve Bulera, about the challenges of drug discovery, why every moment matters, and the benefits of the collaborative approach Charles River takes in working with its partners.
